Sorafenib 400mg twice daily

2 trials

Sponsors

Chiba University Hospital, Sapporo Medical University Hospital

Conditions

Advanced Hepatcellular Carcinomaadvanced hepatocellular carcinoma

Phase 2

Safety and Efficacy Study of Sorafenib in Japanese Child-Pugh A and B Patients with Advanced Hepatocellular Carcinoma

Active, not recruitingJPRN-UMIN000004215

Chiba University HospitalAdvanced Hepatcellular Carcinoma

Start: 2010-05-01Target: 100Updated: 2026-06-29

Unknown Phase

An Investigation of the Safety of Continued Treatment with Sorafenib in Patients with Unresectable Hepatocellular Carcinoma after the First Disease Progression

Active, not recruitingJPRN-UMIN000005818

Sapporo Medical University Hospitaladvanced hepatocellular carcinoma

Start: 2011-06-13Target: 40Updated: 2026-06-29

Related Papers

An investigation of the safety of continued treatment with sorafenib in patients with unresectable hepatocellular carcinoma after the first disease progression: Multicenter, open-label, phase II safety study.

Journal of Clinical Oncology2015-01-20